
-
Black comedy from award-winning 'Parasite' director tops N.America box office
-
EU chief sees US as 'allies' despite 'differences'
-
French research groups urged to welcome scientists fleeing US
-
Journalist quits broadcaster after comparing French actions in Algeria to Nazi massacre
-
Highlights from Paris Women's Fashion Week
-
US ends waiver for Iraq to buy Iranian electricity
-
China-US trade war heats up with Beijing's tariffs to take effect
-
Greenland's Inuits rediscover their national pride
-
Floods, mass power cuts as wild weather bashes eastern Australia
-
Wild weather leaves mass blackouts in Australia
-
China consumption slump deepens as February prices drop
-
Phone bans sweep US schools despite skepticism
-
Some 200 detained after Istanbul Women's Day march: organisers
-
'Grieving': US federal workers thrown into uncertain job market
-
Remains of murdered Indigenous woman found at Canada landfill
-
Women will overthrow Iran's Islamic republic: Nobel laureate
-
Women step into the ring at west African wrestling tournament
-
Trump's tariff rollback brings limited respite as new levies loom
-
Hackman died of natural causes, a week after wife: medical examiner
-
Oops, we tipped it again: Mission over for sideways US lander
-
Cyclone Alfred downgraded to tropical low as it nears Australia
-
Global stocks mixed as Trump shifts on tariffs weighs on sentiment
-
Trump says dairy, lumber tariffs on Canada may come soon
-
Trump cuts $400 mn from Columbia University over anti-Semitism claims
-
US Fed chair flags policy uncertainty but in no rush to adjust rates
-
Adopted orphan brings couple 'paradise' in war-ravaged Gaza
-
Oops, we tipped it again: Mission over for private US lander
-
Greenland's mining bonanza still a distant promise
-
Pope 'stable' as marks three weeks in hospital with breathless audio message
-
Shares slump on Trump tariffs tinkering, jobs
-
Mission over for private US lander after wonky landing
-
Thousands stranded as massive WWII bomb blocks Paris train station
-
UK court cuts longest jail terms on activists, rejects 10 appeals
-
US hiring misses expectations in February as jobs market faces pressure
-
S.Sudan heatwave 'more likely' due to climate change: study
-
US company says Moon mission over after landing sideways again
-
Trump says farmers keen to quit 'terrible' S. Africa welcome in US
-
US stock markets rise as investors track Trump tariffs, jobs
-
US hiring misses expectations in February, jobs market sees pressure
-
Disco, reggae on King Charles's 'eclectic' Apple playlist
-
Australian casino firm strikes deal to avoid liquidity crunch
-
Deposed king's grandson makes low-key return to Egypt
-
Stock markets, bitcoin down as Trump policies roil markets
-
Bangladesh student leader aims to finish what uprising began
-
Japan, Britain stress free trade in Tokyo talks
-
Spain targets men's 'deafening silence' in gender violence battle
-
Spain under pressure to abort nuclear energy phase-out
-
Hungary femicide sparks outcry on gender violence
-
Trial of Maradona's medics to start four years after star's death
-
Women spearhead maternal health revolution in Bangladesh

Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
S.F.Lacroix--CPN